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referred to a gynecologist and subsequently underwent semiannual
surveillance by transvaginal ultrasonography and endometrial cytology.
After 10 years, an endometrial biopsy revealed complex atypical hyper-
plasia. Adnexal masses were not detected upon transvaginal ultraso-
nography and magnetic resonance imaging, and the carbohydrate
antigen-125 level was 15 U/mL (normal, b35 U/mL). Although the
advantages of total abdominal hysterectomy (TAH) with preventive
bilateral salpingo-oophorectomy (BSO) were explained and this ap-Introduction
Tubal intraepithelial carcinoma (TIC) has been proposed to be a
precursor lesion of ovarian carcinoma based on studies of risk-
reducing salpingo-oophorectomy (RRSO) specimens from hereditary
breast and ovarian cancer patients [1]. On the other hand, one case
of TIC has been reported in a patient with Lynch syndrome (LS) [2].
Furthermore, atypical proliferative (borderline) serous tumors account
for only 4% of ovarian carcinomas in patients with LS. Detection of
early-stage ovarian and fallopian tube cancers is difﬁcult even with
close follow-up of high-risk patientswith LS [2–5]. This has complicated
the identiﬁcation of ovarian carcinomas of fallopian tube origin in
patients with LS. Herein, we present a case of ovarian carcinoma in
situ that presumably originated from the fallopian tube in a LS patient.Case
A 34-year-old multipara woman was diagnosed with sigmoid colon
cancer and underwent total colectomy. Her family history matched the
Amsterdam criteria for LS. Genetic testing showed the presence of and Gynecology, Hyogo College
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strongly desired preservation of the ovaries in the absence of an
intraoperative malignancy diagnosis. Laparotomy revealed the adher-
ence of the right fallopian tube to the right ovary and the presence of
exophytic papillary excrescences on the surface of the right ovary
(tumors A and B in Fig. 1). Tumor A was composed of yellowish small
nodules, whereas the adjacent tumor B showed white ﬁne papillary
structures. Tumor B was resected for intraoperative pathologic evalua-
tion and was diagnosed as being malignant. TAH/BSO was performed,
and the hysterectomy specimen indicated complex atypical endometrial
hyperplasia of the uterus. Histopathology revealed tumor A to be an
atypical proliferative (borderline) serous tumor with tubal type epithe-
lium containing a mixture of ciliated and secretory cells (Fig. 2, panels A
and B). Histopathology of tumor B, which was adjacent to tumor A,
revealed a high-grade serous carcinoma in situ. Tumor B showed tubal
type epithelium with a papillary growth pattern that was composed
of stratiﬁed secretory cells with high-grade nuclear atypia. Neither base-
mentmembrane destruction nor invasion of the underlying stromawas
detected. Therefore, serous carcinoma in situ was our ﬁnal diagnosis,
which was conﬁrmed by intradepartmental reviews and extra-
departmental consultations (Fig. 3, panels A and B). Tumor B was
resected for intraoperative diagnosis, and parafﬁn blocks of tumor A
were prepared from the TAH/BSO specimens. Thus, the border of tumors
A and B was not available for microscopic observation. Immunohisto-
chemical analysis of tumor A showed patchy p53 positive staining and
a Ki-67 proliferative index of 20% (Fig. 2, panels C and D). Tumor B
stained more diffusely and strongly for p53 and Ki-67 (proliferative
index, 55%) than tumor A (Fig. 3, panels C and D). The ﬁmbriated end
of the right fallopian tube was unclear because of adhesion to the
ovary. Atypia was not present in the fallopian tube segments. Pelvic
washing was positive. The patient did not wish to receive adjuvant
Fig. 1. Gross appearance of tumors A and B at laparotomy. Tumor A was composed of
yellowish exophytic nodular excrescences, and the adjacent tumor B showed white
exophytic papillary excrescences.
62 K. Inoue et al. / Gynecologic Oncology Reports 5 (2013) 61–63chemotherapy. She is currently alive without evidence of disease
22 months after TAH/BSO.
Discussion
High-grade serous ovarian carcinoma has been presumed to arise
from TIC. Detailed pathological studies of RRSO specimens from
women with inherited BRCA mutations have shown the presence of
TIC, and a precursor of TIC has been found in neighboring tubal cells
that are morphologically normal but immunohistochemically positiveFig. 2. Tumor A. Hematoxylin and eosin (H&E) stain showing exophytic papillary growth com
the lesional cells (panel B; ×400). Immunohistochemical staining of Ki-67 expression. The Ki-
staining showing the patchy expression of p53 (panel D; ×200).for p53, designated as a p53 signature [6]. Low-grade serous ovarian
cancers could also be derived from the tubal epithelium [7], and in
rare cases, high-grade ovarian carcinomas may arise from serous
borderline tumors [8,9].
To our knowledge, a serous borderline tumor that coexists with
high-grade serous carcinoma in situ on the ovarian surface and p53
signatures in patients with LS have not been reported. Dehari et al.
reported 6 cases of sporadic high-grade serous ovarian carcinomas
that presumably progressed from borderline or low-grade tumors
[9]. p53 mutations were not detected in these 6 cases. In contrast, in
our case, the borderline serous tumor (tumor A), even in its earliest
stage of development, and the high-grade serous carcinoma in situ
(tumor B) showed overexpression of p53. This suggests the existence
of a tumorigenic pathway in which p53 mutations give rise to border-
line ovarian tumors that further progress to high-grade carcinomas in
patients with LS. However, adhesions between the right ﬁmbria and
ovary from the previous colon surgerymay have caused ovarian tumors
to originate from the tubal epithelium in this LS patient.
TIC lesions with positive washing have been reported in BRCA
mutation carriers. However, diagnosis of serous ovarian carcinoma in
situ as the only lesion with positive washing is very rare in patients
with LS.Conclusion
We reported a rare case of ovarian carcinoma in situ, with a p53
signature, originating from the fallopian tube epithelium and the
coexistence of serous ovarian carcinoma in situ and serous borderline
tumor in a LS patient.Conﬂict of interest statement
The authors have no ﬁnancial conﬂicts of interest to disclose.posed mostly of a ﬂat proliferation of cells (panel A; ×200) and mild unclear atypia of
67 proliferation index of the tumor cells was 20% (panel C; ×200). Immunohistochemical
Fig. 3. Tumor B. H&E stain showing complex papillary growth consisting of stratiﬁed atypical tumor cells (panel A; ×40) and exophytic growth of heterogeneous tumor cells with high-
grade nuclear atypia, stratiﬁcation, loss of polarity, and absence of stromal invasion (panel B; ×200). Immunohistochemical staining of Ki-67 expression. The Ki-67 proliferation index of
the tumor cells was 55% (panel C; ×200). Immunohistochemical staining showing the patchy expression of p53 (panel D; ×200).
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